Loading...
NPI 1316058217 · Orlando, FL · Family Medicine Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vaxcare LLC is a family medicine physician provider located in Orlando, Florida. This profile covers 21 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Vaxcare LLC |
| Address | 800 N Magnolia Ave Ste 700 |
| City | Orlando |
| State | FL |
| ZIP | 32803 |
| Taxonomy | Family Medicine Physician |
| NPI Enumerated | August 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $45.5M |
| Medicaid | $780 |
VAXCARE LLC’s Medicare activity is overwhelmingly vaccine-focused: the top revenue-driving codes are vaccine products and administration codes (90677, 90662, G0008), and the precomputed top-3 Medicare codes account for 76.4% of the provider’s total Medicare revenue. The detailed CPT/HCPCS mix (pneumococcal, multiple influenza products, SARS–CoV–2 vaccines, and related administration codes) indicates the organization operates primarily as a high-volume immunization provider rather than a traditional primary-care billing mix.
Medicare revenue scale is substantial compared with Medicaid for this entity: lifetime Medicare revenue is $45.5M versus lifetime Medicaid revenue of $783, indicating the practice is effectively single-payer centric with Medicare revenue dominating its billing footprint. Medicaid activity is de minimis in dollar terms and does not materially contribute to the provider’s overall revenue.
The provider is a national outlier on several Medicare codes. VAXCARE ranks at or near the top nationally for multiple vaccine codes — including #1 of 52451 on 90677, #2 of 70752 on 90662, and #2 of 119096 on G0008 — and these ranks are labeled as "extreme outlier" or equivalent, signaling volumes far above typical national peers for those services. This competitive standing identifies VAXCARE as a dominant national supplier for those specific vaccine products and administration events.
Within Medicaid (in-state), the provider reports nonzero vaccine volumes but at routine state-level rankings. Top Medicaid codes 90471 and 90686 together account for essentially all Medicaid revenue (90471 and 90686 together make up 96.5% of the $783), yet their in-state ranks are midrange (57th and 60th percentiles respectively) and described as "typical, unremarkable" for Florida peers, reflecting normal Medicaid participation rather than market dominance.
Revenue concentration on Medicare is highly skewed: the precomputed statement that the top 3 Medicare codes account for 76.4% of Medicare revenue highlights dependency on a small set of vaccine products and administration codes for most of the $45.5M in Medicare receipts. That concentration implies the provider’s financial performance is tightly coupled to immunization volumes and reimbursements for those specific codes.
Several other Medicare vaccine codes also appear as extreme outliers nationally (e.g., G0009 rank #1, 90732 rank #1, 90670 rank #1), reinforcing that the provider’s operational model centers on delivering large volumes of specific vaccines across multiple formulations. The breadth of high national rankings across influenza, pneumococcal, and COVID‑19 vaccine codes suggests systematic, large-scale vaccination operations rather than sporadic or episodic immunizations.
The provider’s NPI has been enumerated for about 20 years (registered 2006-08-31), indicating long tenure in the marketplace. This longevity, combined with concentrated vaccine billing and national high ranks, suggests an established immunization-focused business that has scaled its vaccine delivery over time.
Despite extremely high Medicare volumes, several Medicaid claims report $0 paid amounts for common vaccine administration codes (e.g., G0008 and 90662 show claims but $0 revenue in Medicaid), which may reflect payer reimbursement policies, encounter reporting without payment, or data coding differences rather than substantive clinical volume differences. Analysts should treat Medicaid dollar figures cautiously given the small $783 lifetime revenue and multiple $0-paid code entries.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 54,680 | $280 | $15.4M |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 179,410 | $70 | $12.9M |
| G0008 | Administration of influenza virus vaccine | 217,360 | $30 | $6.5M |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 16,520 | $130 | $2.1M |
| G0009 | Administration of pneumococcal vaccine | 66,790 | $30 | $2M |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 11,640 | $140 | $1.7M |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 28,180 | $40 | $1.1M |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 8,330 | $130 | $1.1M |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 13,510 | $80 | $1M |
| 90670 | This code represents a pneumococcal vaccine product administered into the muscle to protect against 13 types of pneumococcal bacteria that can cause serious infections like pneumonia, meningitis, and… | 2,600 | $250 | $656.8K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 90671 | 1 | 20 | 20 | $240 | $22K |
| 90670 | 1 | 40 | 20 | $250 | $21.8K |
| 91322 | 1 | 1,790 | 80 | $140 | $17.6K |
| 91320 | 1 | 1,440 | 70 | $130 | $15.5K |
| 90677 | 1 | 3,290 | 20 | $280 | $13.5K |
| 90694 | 1 | 3,460 | 70 | $70 | $9.7K |
| 90732 | 1 | 210 | 20 | $130 | $7.9K |
| 90662 | 1 | 3,870 | 40 | $70 | $7.6K |
| 90480 | 1 | 2,990 | 90 | $40 | $5.2K |
| 90682 | 1 | 30 | 10 | $70 | $4.6K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 350 | $1 | $700 |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 330 | $1 | $330 |
| 90460 | In this procedure, the provider administers a single live attenuated vaccine through a parenteral, oral, intranasal, intramuscular, or intravenous to a patient up to 18 years of age. | 40 | $1 | $40 |
| 90461 | In this procedure, the provider administers an additional live attenuated vaccine either via a parenteral, oral, intranasal, intramuscular, or intravenous to a patient up to 18 years of age after the… | 20 | $0 | $0 |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 20 | $0 | $0 |
| 90661 | This code represents a vaccine product administered into the muscle to protect against the flu virus. This is a trivalent vaccine, meaning it protects against three different strains of influenza.… | 10 | $0 | $0 |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 210 | $0 | $0 |
| G0008 | Administration of influenza virus vaccine | 380 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90460 | In this procedure, the provider administers a single live attenuated vaccine through a parenteral, oral, intranasal, intramuscular, or intravenous to a patient up to 18 years of age. | 1,025 | 1,140 | 1,240 | $10 | $70.8K |
| 90461 | In this procedure, the provider administers an additional live attenuated vaccine either via a parenteral, oral, intranasal, intramuscular, or intravenous to a patient up to 18 years of age after the… | 677 | 720 | 490 | $10 | $21.4K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 387 | 900 | 210 | $1 | $7.7K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 503 | 1,270 | 160 | $1 | $2K |
| G0008 | Administration of influenza virus vaccine | 26 | 1,050 | 60 | $20 | $1.6K |
| 90661 | This code represents a vaccine product administered into the muscle to protect against the flu virus. This is a trivalent vaccine, meaning it protects against three different strains of influenza.… | 30 | 40 | 30 | $10 | $910 |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 11 | 300 | 40 | $10 | $420 |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 303 | 390 | 50 | $1 | $150 |
Other providers in the same ZIP code as Vaxcare LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.